longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Arbutus Pharma

ABUS

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 6.24, above the reasonable range, cheaper than 2.22% of the time in the past 5 years, and the industry ranks 22/603, the industry Median -2.26.

6.24xP/E
$4.85Stock price
$0.78Earnings per share
6.24xP/E
Stock price$4.85Earnings per share$0.78

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-6.03x
Typical range
-9.48x–-4.50x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GRFSUSGRIFOLS SA
9.63x42.44%$5.05B
ACADUSAcadia Pharma
9.37x73.45%$3.56B
PURRUSHyperliquid Strategies
9.92x84.74%$2.54B
AUPHUSAurinia Pharma
6.96x54.40%$2.19B
ADMAUSAdma Biologics
12.43x35.42%$2.10B
LKFTUSLakefront Biotherapeutics
2.76x86.19%$1.91B
ANABUSAnaptysbio
5.82x1,051.46%$1.52B
VORUSVor BioPharma
1.75x89.77%$1.10B
MGTXUSMeiraGTx
13.27x122.03%$1.05B
ABUSUSArbutus Pharma
6.24x533.09%$955.16M
RIGLUSRigel Pharma
2.80x83.91%$900.00M
BVNRYUSBavarian Nordic A/S
3.49x--$835.80M
IRWDUSIronwood Pharma
5.25x715.55%$682.44M
AGENUSAgenus
4.19x--$384.47M
CUVLUSClinuvel Pharmaceuticals
12.39x--$283.91M
QTTBUSQ32 Bio
7.73x162.23%$261.08M
CGENUSCompugen
6.41x173.68%$225.44M
PLXUSProtalix Biotherap
11.57x400.00%$219.15M
VXRTUSVaxart
2.87x328.57%$110.62M
RLYBUSRallybio
1.94x131.45%$88.26M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.